Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents.
Biomed Pharmacother
; 118: 109289, 2019 Oct.
Article
en En
| MEDLINE
| ID: mdl-31401398
Palabras clave
ABC transporter; ABCC1; Afatinib (PubChem CID: 10184653); Alisertib (PubChem CID: 24771867); Alvespimycin (PubChem CID: 5288674); Amuvatinib (PubChem CID: 11282283); Anti-cancer agent; Celecoxib (PubChem CID: 2662); Doramapimod (PubChem CID: 156422); Doxorubicin; Drug absorption and disposition; Drug profiling; Drug-transporter interactions; Flavopiridol (PubChem CID: 5287969); GSK2126458 (PubChem CID: 25167777); GSK461364 (PubChem CID: 15983966); GW4064 (PubChem CID: 9893571); High content screening; LY2228820 (PubChem CID: 11570805); LY294002 (PubChem CID: 3973); MK-2206 (PubChem CID: 24964624); MRP1; MRP1 inhibitors; Mifepristone (PubChem CID: 55245); Multidrug resistance; NVP-BSK805 (PubChem CID: 57339395); OSI-420 (PubChem CID: 18924996); Rosiglitazone (PubChem CID: 77999); Saracatinib (PubChem CID: 10302451)
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Doxorrubicina
/
Proteínas Asociadas a Resistencia a Múltiples Medicamentos
/
Ensayos Analíticos de Alto Rendimiento
/
Fluoresceínas
/
Colorantes Fluorescentes
/
Antineoplásicos
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
/
Screening_studies
Límite:
Humans
Idioma:
En
Revista:
Biomed Pharmacother
Año:
2019
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Francia